Canakinumab for the treatment of familial Mediterranean fever

Expert Review of Clinical Immunology

Volumn 13, Issue 5, 2017, Pages 393-404

  Ozdogan, Huri ^a   Ugurlu, Serdal ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Anti IL 1 drugs; Canakinumab; colchicine resistant familial Mediterranean fever; familial Mediterranean fever; hereditary periodic fever syndromes; IL 1

Indexed keywords

ANAKINRA; CANAKINUMAB; COLCHICINE; INTERLEUKIN 1BETA ANTIBODY; RILONACEPT; INTERLEUKIN 1BETA; MEFV PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PYRIN;

ARTICLE; CASE REPORT; CASE STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL MEDITERRANEAN FEVER; FOLLOW UP; HUMAN; PHARMACEUTICAL CARE; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); CLINICAL TRIAL (TOPIC); FOOD AND DRUG ADMINISTRATION; GENETICS; IMMUNOLOGY; MUTATION; TREATMENT OUTCOME; UNITED STATES;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; FAMILIAL MEDITERRANEAN FEVER; HUMANS; INTERLEUKIN-1BETA; MUTATION; PYRIN; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85017207810     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2017.1313116     Document Type: Article

References (96)

1. Ben-Chetrit E, Touitou I., Familial mediterranean Fever in the world. Arthritis Rheum. 2009;61:1447–1453.• This important review gives a perspective of the world-wide distribution and prevalence of FMF.
2. Yilmaz E, Ozen S, Balci B, et al. Mutation frequency of familial mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001;9:553–555.
3. Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 2001;9:473–483.
4. Cuisset L, Jeru I, Dumont B, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene:epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis. 2011;70:495–499.
5. K Iy M, Jiuchi Y, Iwanaga N, et al. Familial Mediterranean fever is no longer a rare disease in Japan. Arthritis Res Ther. 2016;30:175.
6. Papadopoulos VP, Giaglis S, Mitroulis I, et al. The population genetics of familial mediterranean fever:a meta-analysis study. Ann Hum Genet. 2008;72:752–761.
7. Sohar E, Gafni J, Pras M, et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43:227–253.
8. French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17:25–31.
9. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90:797–807.
10. Infevers. Available from:http://fmf.igh.cnrs.fr/ISSAID/infevers/
11. Yang J, Xu H, Shao F. Immunological function of familial Mediterranean fever disease protein Pyrin. Sci China Life Sci. 2014;57:1156–1161.
12. Grandemange S, Aksentijevich I, Jeru I, et al. The regulation of MEFV expression and its role in health and familial Mediterranean fever. Genes Immun. 2011;12:497–503.
13. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006;103:9982–9987.•• This significant study reports the ASC-independent effect of pyrin on IL-1beta activation, and describes the effect of FMF-associated mutations as less of an inhibitory but rather increase in innate immune responses.
14. Booth DR, Gillmore JD, Lachmann HJ, et al. The genetic basis of autosomal dominant familial Mediterranean fever. QJM. 2000;93:217–221.
15. Chae JJ, Cho YH, Lee GS, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity. 2011;34:755–768.
16. Park YH, Wood G, Kastner DL, et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016;17:914–921.•• This original paper shows that RhoA signalling is effected via two different pathways but the common result is the activation of pyrin inflammasome in FMF and HIDS/MVK.
17. Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature. 2014;513:237–241.•• This important study gives insight not only to the physiological function of pyrin but also contributes to better understanding of innate immunity.
18. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302.• This is one of the most famous Letter to the Editor ever published which showed that colchicine was effective in FMF attacks if given prophylactically.
19. Ozkan E, Okur O, Ekmekci A, et al. A new approach to the treatment of periodic fever. Med Bull Istanbul. 1972;5:44–49.• However not widely recognised as Goldfinger’s letter to the editor, this paper published in the same year, is one of the initial 2 papers on the efficacy of daily colchicine therapy. It reports on 14 patients, one with amyloidosis.
20. Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med. 1974;291:934–937.
21. Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med. 1974;291:932–934.
22. Zemer D, Livneh A, Danon YL, et al. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 1991;34:973–977.
23. Ben-Chetrit E, Levy M. Colchicine:1998 update. Semin Arthritis Rheum. 1998;28:48–59.
24. Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr. 2012;161:1142–1146.
25. Slobodnick A, Shah B, Pillinger MH, et al. Colchicine:old and new. Am J Med. 2015;128:461–470.
26. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659–664.
27. Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever:literature review and consensus statement. Pediatrics. 2007;119:e474–83.
28. Korkmaz C, Ozdogan H, Kasapcopur O, et al. Acute phase response in familial Mediterranean fever. Ann Rheum Dis. 2002;61:79–81.
29. Lachmann HJ, Sengul B, Yavuzsen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45:746–750.
30. Ben-Chetrit E, Ozdogan H. Non-response to colchicine in FMF–definition, causes and suggested solutions. Clin Exp Rheumatol. 2008;26:S49–51.
31. Ozen S, Demirkaya E, Duzova A, et al. FMF50:a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis. 2014;73:897–901.
32. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum. 2013;43:387–391.
33. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644–651.• These recommendations offer a general approach to the treatment of FMF as well as address specific issues such as colchicine resistance and alternative treatments, prepared by the contribution of a group of experts in FMF.
34. Tunca M, Akar S, Soyturk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever:A double-blind, placebo-controlled trial. Clin Exp Rheumatol. 2004;22:S37–40.
35. Sayarlioglu H, Erkoc R, Sayarlioglu M, et al. Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine:report of three Turkish cases. Rheumatol Int. 2006;27:197–199.
36. Seyahi E, Ozdogan H, Celik S, et al. Treatment options in colchicine resistant familial Mediterranean fever patients:thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol. 2006;24:S99–103.
37. Fujikawa K, Migita K, Tsukada T, et al. Interleukin-6 targeting therapy in familial Mediterranean fever. Clin Exp Rheumatol. 2013;31(3 Suppl 77):150–151.
38. Umeda M, Aramaki T, Fujikawa K, et al. Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis. Int J Rheum Dis. 2015 Oct 20. DOI:10.1111/1756-185X.12776.
39. Van Der Hilst J, Moutschen M, Messiaen PE, et al. Efficacy of anti-IL-1 treatment in familial Mediterranean fever:a systematic review of the literature. Biologics. 2016;10:75–80.
40. Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever:a randomized trial. Ann Intern Med. 2012;157:533–541.
41. De Benedetti F, Anton J, Ben-Chetrit E, et al. Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD AND TRAPS):results from a Phase 3, Pivotal, Umbrella Trial [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). [cited 2016 Nov22]. Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-canakinumab-in-patients-with-periodic-fever-syndromes-colchicine-resistant-fmf-hidsmkd-and-traps-results-from-a-phase-3-pivotal-umbrella-trial/.•• However still ongoing, this is the only randomized, placebo-controlled Phase III trial with canakinumab in crFMF, along with TRAPS and HIDS/MVK.
42. De Benedetti F, Frenkel J, Calvo I, et al. Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever, Hyper-Immunoglobulin D Syndrome/Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome:40 Week Results from the Pivotal Phase 3 Umbrella Cluster Trial [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). [cited 2016 Nov22]. Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-canakinumab-in-patients-with-colchicine-resistant-familial-mediterranean-fever-hyper-immunoglobulin-d-syndromemevalonate-kinase-deficiency-and-tnf-receptor-associated-periodic/.•• However still ongoing, this is the only randomized, placebo-controlled Phase III trial with canakinumab in crFMF, along with TRAPS and HIDS/MVK(40 week).
43. Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for colchicine resistant familial Mediterranean fever - A randomized, double blind, placebo-controlled trial. Arthritis Rheumatol. 2016 cited 2016 Nov22. DOI:10.1002/art.39995.
44. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425.
45. Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–567.
46. Drug information. Available from: https://www.uptodate.com/contents/anakinra-drug- information?source=search_result&search=anakinra&selectedTitle=1~92
47. Drug information. Available from: https://www.uptodate.com/contents/rilonacept-drug-information?source=search_result&search=rilonacept&selectedTitle=1~20
48. Drug information. Available from: https://www.uptodate.com/contents/canakinumab-drug-information?source=search_result&search=canakinumab&selectedTitle=1~21
49. Kone-Paut I, Galeotti C. Anakinra for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol. 2014;10:7–18.
50. Georgin-Lavialle S, Stankovic Stojanovic K, Bachmeyer C, et al. Spondyloarthritis associated with familial Mediterranean fever:successful treatment with anakinra. Rheumatology (Oxford). 2017;56(1):167–169.
51. Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France:a nationwide survey. Orphanet J Rare Dis. 2015;10:19.
52. Ozdogan H, Ugurlu S. The emerging treatments in familial Mediterranean fever. In:Gattorno M, editor. Familial Mediterranean fever. Switzerland:SpringerInternational Publishing; 2015. p. 137–158.
53. Espildora-Hernandez J, Abarca-Costalago M. Familial mediterranean fever treated with anakinra:A case report. Reumatol Clin. 2016 [cited 2016 Nov20]. English, Spanish. DOI:10.1016/j.reuma.2016.06.001.
54. Kucuksahin O, Yildizgoren MT, Ilgen U, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever. Mod Rheumatol. 2017;27(2):350–355.
55. Abbara S, Georgin-Lavialle S, Stankovic Stojanovic K, et al. Association of hidradenitis suppurativa and familial Mediterranean fever:A case series of 6 patients. Joint Bone Spine. 2017;84(2):159–162.
56. Dinarello CA, Simon A, Van Der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633–652.
57. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes:results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58:2443–2452.
58. Lovell DJ, Giannini EH, Aor R, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:2486–2496.
59. Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy:results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford). 2013;52:1285–1292.
60. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11:81–89.
61. Gram H. Preclinical characterization and clinical development of ILARIS((R)) (canakinumab) for the treatment of autoinflammatory diseases. Curr Opin Chem Biol. 2016;32:1–9.
62. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70:2095–2102.
63. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–2406.
64. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options:results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71:1839–1848.
65. Sun H, Van LM, Floch D, et al. Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis. J Clin Pharmacol. 2016;56(12):1516–1527.
66. Chakraborty A, Van LM, Skerjanec A, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. J Clin Pharmacol. 2013;53:1240–1251.
67. Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet. 2012;51:e1–18.
68. Alten R, Gram H, La J, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R67.
69. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med. 2009;206:1029–1036.
70. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–558.
71. Frenkel JAJ, Livneh A, Ben-Chetrit E, et al. Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes:results from a Phase III Pivotal Umbrella Trial [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). [cited 2016 Nov22]. Available from: http://acrabstracts.org/abstract/pharmacokinetic-and-pharmacodynamic-characteristics-of-canakinumab-in-patients-with-periodic-fever-syndromes-results-from-a-phase-iii-pivotal-umbrella-trial/.•• This abstract reports for the first time the pharmacokinetics and pharmacodynamics of canakinumab given as a solution for injection –liquid in vial (LIVI) form. The results were comparible with the previously used lyophilisate form.
72. Mitroulis I, Skendros P, Oikonomou A, et al. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011;70:1347–1348.
73. Meinzer U, Quartier P, Alexandra JF, et al. Interleukin-1 targeting drugs in familial Mediterranean fever:a case series and a review of the literature. Semin Arthritis Rheum. 2011;41:265–271.
74. Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology (Oxford). 2012;51:1041.
75. Alpa M, Roccatello D. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment. Drug Des Devel Ther. 2015;9:1983–1987.
76. Cetin P, Sari I, Sozeri B, et al. Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean. Fever Inflammation. 2015;38:27–31.
77. Basaran O, Uncu N, Celikel BA, et al. Interleukin-1 targeting treatment in familial Mediterranean fever:an experience of pediatric patients. Mod Rheumatol. 2015;25:621–624.
78. Eroglu FK, Besbas N, Topaloglu R, et al. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int. 2015;35:1733–1737.
79. Ozcakar ZB, Ozdel S, Yilmaz S, et al. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35:441–446.
80. Sozeri B, Gulez N, Ergin M, et al. The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever. Mol Cell Pediatr. 2016;3:33.
81. Brik R, Butbul-Aviel Y, Lubin S, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever:a 6-month open-label, single-arm pilot study. Arthritis Rheumatol. 2014;66:3241–3243.•• This is one of the two Phase II study performed in 7 children from Israel.
82. Gul A, Ozdogan H, Erer B, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015;17:243.•• The other the two Phase II studies with canakinumab, conducted in 9 Turkish adult and adolescent FMF patients.
83. Ugurlu S, Seyahi E, Hatemi G, et al. Canakinumab Therapy in Patients with Familial Mediterranean Fever [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). [cited 2016 Nov22]. Available from: http://acrabstracts.org/abstract/canakinumab-therapy-in-patients-with-familial-mediterranean-fever-2/.• This abstract has the largest group of patients treated with canakinumab (n=32) as well as the largest group with amyloidosis (n=6).
84. Laskari K, Boura P, Dalekos G, et al. The Interleukin-1 Inhibitor Canakinumab for Familial Mediterranean Fever:long-Term Beneficial Effect in a Cohort of 13 Patients [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). [cited 2016 Nov22]. Available from: http://acrabstracts.org/abstract/the-interleukin-1-inhibitor-canakinumab-for-familial-mediterranean-fever-long-term-beneficial-effect-in-a-cohort-of-13-patients/
85. Gul A, Ozdogan H, Kasapcopur O, et al. Quality of Life Changes with Canakinumab Therapy in Adults with Colchicine Resistant FMF [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). [cited 2016 Nov22]. Available from: http://acrabstracts.org/abstract/quality-of-life-changes-with-canakinumab-therapy-in-adults-with-colchicine-resistant-fmf/
86. Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS):an open-label, phase II study. Ann Rheum Dis. 2016 [cited 22Nov 2016]. DOI:10.1136/annrheumdis-2015-209031.• This Phase II study in 20 TRAPS patients reports a very rapid dramatic response which was sustained through out the follow-up period.
87. Simon A, Shcherbina A, Anton J, et al. Effect of Canakinumab Treatment on Health-Related Quality of Life in Patients with Periodic Fever Syndromes [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). [cited 2016 Nov22]. Available from: http://acrabstracts.org/abstract/effect-of-canakinumab-treatment-on-health-related-quality-of-life-in-patients-with-periodic-fever-syndromes/
88. Hashkes P, Butbul Aviel Y, Lubin S, et al. A76:long‐Term Efficacy of Canakinumab in Childhood Colchicine Resistant Familial Mediterranean Fever. Arthritis Rheumatol. 2014;66(S3):S108–S108.
89. Hosono K, Okami N, Sasajima T, et al. A 3-year interim analysis of post-marketing all-patient surveillance of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome. Clin Rheumatol Relat Res. 2016;28:53–65.
90. Kuemmerle-Deschner J, Hoffman H, Hawkins PN, et al. Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients:results from beta-confident registry. Pediatr Rheumatol. 2015;13(1):1.• This paper reminds us about the importance of registries, especially to obtain the follow-up safety and efficacy data in rare diseases.
91. Youngstein T, Hoffmann P, Lane T, et al. International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors. Pediatr Rheumatol. 2015;13(1):1.
92. Akse-Onal V, Sag E, Ozen S, et al. Decrease in the rate of secondary amyloidosis in Turkish children with FMF:are we doing better? Eur J Pediatr. 2010;169:971–974.
93. Belkhir R, Moulonguet-Doleris L, Hachulla E, et al. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med. 2007;146:825–826.
94. Demirkaya E, Acikel C, Hashkes P, et al. Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis. 2016;75:1051–1056.
95. Haviv R, Hashkes PJ. Canakinumab investigated for treating familial Mediterranean fever. Expert Opin Biol Ther. 2016;16:1425–1434.
96. Eurofever project. Available from: http://www.printo.it/eurofever